Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Water. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 known ✓ | O00255 | 1/20 | 0.57 |
| ▸ | DNM1 | Q05193 | 9/20 | 0.89 |
| ▸ | CA12 | O43570 | 2/20 | 0.89 |
| ▸ | CA1 | P00915 | 2/20 | 0.89 |
| ▸ | CA2 | P00918 | 2/20 | 0.89 |
| ▸ | CA3 | P07451 | 2/20 | 0.89 |
| ▸ | CA4 | P22748 | 2/20 | 0.89 |
| ▸ | CA6 | P23280 | 2/20 | 0.89 |
| ▸ | CA5A | P35218 | 2/20 | 0.89 |
| ▸ | CA7 | P43166 | 2/20 | 0.89 |
| ▸ | CA9 | Q16790 | 2/20 | 0.89 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.89 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.89 |
| ▸ | TSHR | P16473 | 2/20 | 0.89 |
| ▸ | LMNA | P02545 | 1/20 | 0.89 |
| ▸ | BLM | P54132 | 1/20 | 0.89 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.78 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL28172776 | 1.00 | DNM1 (0.89) | DNM1CA12CA1CA2CA3 | |
| Water SCHEMBL31147094 | 1.00 | DNM1 (0.89) | DNM1CA12CA1CA2CA3 | |
| Water SCHEMBL27506242 | 1.00 | DNM1 (0.89) | DNM1CA12CA1CA2CA3 | |
| Water SCHEMBL27567442 | 1.00 | DNM1 (0.89) | DNM1CA12CA1CA2CA3 | |
| Water SCHEMBL5492049 | 1.00 | — | — | |
| Water SCHEMBL27524665 | 0.95 | DNM1 (0.80) | DNM1CA12CA1CA2CA3 | |
| Water SCHEMBL15710762 | 0.95 | DNM1 (0.80) | DNM1CA12CA1CA2CA3 | |
| Hydrochloric Acid SCHEMBL28962554 | 0.95 | DNM1 (0.80) | DNM1CA12CA1CA2CA3 | |
| SCHEMBL25262966 | 0.94 | DNM1 (1.00) | DNM1CA12CA1CA2CA3 | |
| SCHEMBL22684930 | 0.94 | DNM1 (1.00) | DNM1CA12CA1CA2CA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119750607-A | Nano rod-shaped ZSM-48 molecular sieve, preparation method thereof, hydroisomerization catalyst and application thereof | 国家能源集团宁夏煤业有限责任公司 | 2025-04-04 | — | — | CN | claimed |
| CN-119750607-A | Nano rod-shaped ZSM-48 molecular sieve, preparation method thereof, hydroisomerization catalyst and application thereof | 国家能源集团宁夏煤业有限责任公司 | 2025-04-04 | — | — | CN | disclosed |
| CN-112585092-B | Molecular sieve and method for manufacturing molecular sieve | 埃克森美孚科技工程公司 | 2025-03-04 | — | — | CN | disclosed |
| EP-3545958-B1 | SALTS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF | ESSENTIALIS INC (US) | 2024-07-10 | — | — | EP | disclosed |
| CN-117583020-A | Zeolite having improved hydroisomerization reactivity | SK新技术株式会社 | 2024-02-23 | — | — | CN | disclosed |
| CN-113603108-B | O-Si-Al-Zr ternary framework AEI molecular sieve and synthesis method thereof | 威海佰德信新材料有限公司 | 2024-01-30 | — | — | CN | disclosed |
| US-11786536-B2 | Salts of potassium ATP channel openers and uses thereof | ESSENTIALIS, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| CN-113860327-B | ERI type magnesium-silicon-aluminum molecular sieve, synthesis method and application thereof | 中国石油化工股份有限公司 | 2023-07-04 | — | — | CN | disclosed |
| US-20220047605-A1 | SALTS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF | SOLENO THERAPEUTICS, INC. | 2022-02-17 | — | — | US | disclosed |
| CN-108602052-B | High charge density metal phosphate molecular sieves | 环球油品公司 | 2021-11-26 | — | — | CN | disclosed |
| US-20090148526-A1 | SALTS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF | ESSENTIALIS, INC. | 2009-06-11 | — | — | US | disclosed |
| US-20090062264-A1 | SALTS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF | SOLENO THERAPEUTICS, INC. | 2009-03-05 | — | — | US | disclosed |
| EP-1968601-A4 | SALTS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF | ESSENTIALIS INC (US) | 2009-02-25 | — | — | EP | disclosed |
| WO-2009006483-A1 | SALTS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF | ESSENTIALIS, INC. (US) | 2009-01-08 | — | — | WO | disclosed |
| EP-1968601-A2 | SALTS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF | Essentialis, Inc. (US) | 2008-09-17 | — | — | EP | disclosed |
| US-20070191351-A1 | SALTS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF | SOLENO THERAPEUTICS, INC. | 2007-08-16 | — | — | US | disclosed |
| WO-2007081521-A2 | SALTS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF | ESSENTIALIS, INC. (US) | 2007-07-19 | — | — | WO | disclosed |
| CN-1291914-C | Synthetic porous crystalline material ITQ-13, its synthesis and use | EXXONMOBIL RES & ENG CO (US) | 2006-12-27 | — | — | CN | disclosed |
| CN-1512965-A | Synthetic porous crystalline mateial ITQ-3, its synthesis and use | ����ɭ�о����̹�˾ | 2004-07-14 | — | — | CN | disclosed |
| US-5623088-A | TETRASUBSTITUTED AMMONIUM SALT CHEMICAL INTERMEDIATES OBTAINED FROM REACTING NITROBENZENE, ANILINE IN PRESENCE OF A BASE; HALOGEN-FREE PROCESS | FLEXSYS AMERICA L. P. (US) | 1997-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220047605-A1 | SALTS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF | KCNJ1, KCNJ11, KCNJ2 | MEN1 1436/4885DNM1 967/4885CA12 4541/4885 |
| US-20070191351-A1 | SALTS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF | KCNJ1, KCNJ11, KCNJ2 | MEN1 1436/4885DNM1 967/4885CA12 4541/4885 |
| US-20090062264-A1 | SALTS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF | KCNJ1, KCNJ11, KCNJ2 | MEN1 1436/4885DNM1 967/4885CA12 4541/4885 |
| US-11786536-B2 | Salts of potassium ATP channel openers and uses thereof | KCNJ1, KCNJ11, KCNJ2 | MEN1 1436/4885DNM1 967/4885CA12 4541/4885 |
| US-20090148526-A1 | SALTS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF | KCNJ1, KCNJ11, KCNJ2 | MEN1 1436/4885DNM1 967/4885CA12 4541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.